Avadel Pharmaceuticals (AVDL) announced today that LUMRYZ has been granted Orphan Drug Designation, ODD, from the U.S. Food & Drug Administration, FDA, for the treatment of Idiopathic Hypersomnia. Specifically, ODD was granted based on the plausible hypothesis that LUMRYZ may be clinically superior to the same drug already approved for the same indication, because LUMRYZ may provide a major contribution to patient care due to its once-nightly dosing for patients with IH, a chronic sleep disorder that requires potentially lifelong treatment.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals appoints Susan Rodriguez as COO
- Avadel Pharmaceuticals Appoints New Chief Operating Officer
- Avadel Pharmaceuticals Sees Strong Q1 Growth, Raises Guidance
- Avadel Pharmaceuticals’ Earnings Call Highlights Growth and Optimism
- Avadel Pharmaceuticals reports Q1 EPS (5c), consensus (7c)